Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker TARA
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | JANUS HENDERSON GROUP Ltd. | 4.70M | 8.4% | SCHEDULE 13G/A ↗ |
| Jul 7, 2026 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Israel A. Englander | 3.20M | 5.7% | SCHEDULE 13G/A ↗ |
| Jul 7, 2026 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Millennium Group Management LLC | 3.20M | 5.7% | SCHEDULE 13G/A ↗ |
| Jul 7, 2026 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Millennium Management LLC | 3.20M | 5.7% | SCHEDULE 13G/A ↗ |
| Jul 7, 2026 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Integrated Core Strategies (US) LLC | 2.88M | 5.1% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Janus Henderson Group PLC | 5.21M | 9.6% | SCHEDULE 13G/A ↗ |
| Apr 27, 2026 | SCHEDULE 13G | TARA Protara Therapeutics, Inc. | BlackRock, Inc. | 3.39M | 6.3% | SCHEDULE 13G ↗ |
| Mar 2, 2026 | SCHEDULE 13G | TARA Protara Therapeutics, Inc. | Israel A. Englander | 2.76M | 5.1% | SCHEDULE 13G ↗ |
| Mar 2, 2026 | SCHEDULE 13G | TARA Protara Therapeutics, Inc. | Millennium Group Management LLC | 2.76M | 5.1% | SCHEDULE 13G ↗ |
| Mar 2, 2026 | SCHEDULE 13G | TARA Protara Therapeutics, Inc. | Millennium Management LLC | 2.76M | 5.1% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Janus Henderson Group PLC | 5.14M | 10.0% | SCHEDULE 13G/A ↗ |
| Jan 21, 2026 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | BlackRock, Inc. | 2.41M | 4.7% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Janus Henderson Biotech Innovation Master Fund Ltd | 3.58M | 9.3% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Janus Henderson Group PLC | 4.23M | 11.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | RA Capital Healthcare Fund, L.P. | 1.97M | 4.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Rajeev Shah | 1.97M | 4.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Peter Kolchinsky | 1.97M | 4.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | RA Capital Management, L.P. | 1.97M | 4.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Janus Henderson Biotech Innovation Master Fund Ltd | 3.51M | 9.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Janus Henderson Group PLC | 4.10M | 10.6% | SCHEDULE 13G/A ↗ |
| Jul 17, 2025 | SCHEDULE 13G | TARA Protara Therapeutics, Inc. | BlackRock, Inc. | 2.14M | 5.6% | SCHEDULE 13G ↗ |
| May 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Janus Henderson Biotech Innovation Master Fund Ltd | 3.36M | 9.1% | SCHEDULE 13G/A ↗ |
| May 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Janus Henderson Group PLC | 3.86M | 10.5% | SCHEDULE 13G/A ↗ |
| May 12, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Phillip Gross | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 12, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Robert Atchinson | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 12, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Adage Capital Management, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Apr 28, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Opaleye Management, Inc. | 1.73M | 4.7% | SCHEDULE 13G/A ↗ |
| Mar 7, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Janus Henderson Biotech Innovation Master Fund Ltd | 3.36M | 9.1% | SCHEDULE 13G/A ↗ |
| Mar 7, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Janus Henderson Group PLC | 3.79M | 10.3% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Opaleye Management, Inc. | 1.82M | 5.3% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | RA Capital Healthcare Fund, L.P. | 3.43M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Rajeev Shah | 3.43M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Peter Kolchinsky | 3.43M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | RA Capital Management, L.P. | 3.43M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G | TARA Protara Therapeutics, Inc. | Janus Henderson Biotech Innovation Master Fund Ltd | 5.45M | 6.0% | SCHEDULE 13G ↗ |
| Feb 14, 2025 | SCHEDULE 13G | TARA Protara Therapeutics, Inc. | Janus Henderson Group PLC | 2.27M | 6.6% | SCHEDULE 13G ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Kenneth Griffin | 1.63M | 4.7% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Citadel Securities GP LLC | 15,203 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Citadel Securities Group LP | 15,203 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Citadel Securities LLC | 15,203 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Citadel GP LLC | 1.61M | 4.6% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Citadel Advisors Holdings LP | 1.61M | 4.6% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Citadel Advisors LLC | 1.61M | 4.6% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | TARA Protara Therapeutics, Inc. | Woodline Partners LP | 1.33M | 3.9% | SCHEDULE 13G/A ↗ |
| Feb 12, 2025 | SCHEDULE 13G | TARA Protara Therapeutics, Inc. | Phillip Gross | 2.25M | 6.6% | SCHEDULE 13G ↗ |
| Feb 12, 2025 | SCHEDULE 13G | TARA Protara Therapeutics, Inc. | Robert Atchinson | 2.25M | 6.6% | SCHEDULE 13G ↗ |
| Feb 12, 2025 | SCHEDULE 13G | TARA Protara Therapeutics, Inc. | Adage Capital Management, L.P. | 2.25M | 6.6% | SCHEDULE 13G ↗ |
47 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 7:25 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances